BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghias MH, Hyde MJ, Tomalin LE, Morgan BP, Alavi A, Lowes MA, Piguet V. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. J Invest Dermatol 2020;140:531-536.e1. [PMID: 31870626 DOI: 10.1016/j.jid.2019.09.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Alavi A, Lowes MA, Lu JD, Xu Z, Habel M, Guo R, Piguet V. Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target. J Cutan Med Surg 2021;25:449-50. [PMID: 33626897 DOI: 10.1177/1203475421995180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhou HY, Cao NW, Guo B, Chen WJ, Tao JH, Chu XJ, Meng X, Zhang TX, Li BZ. Systemic lupus erythematosus patients have a distinct structural and functional skin microbiota compared with controls. Lupus 2021;:9612033211025095. [PMID: 34139926 DOI: 10.1177/09612033211025095] [Reference Citation Analysis]
3 Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. J Allergy Clin Immunol 2021:S0091-6749(21)00832-0. [PMID: 34081946 DOI: 10.1016/j.jaci.2021.05.027] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Rosi E, Fastame MT, Scandagli I, Di Cesare A, Ricceri F, Pimpinelli N, Prignano F. Insights into the Pathogenesis of HS and Therapeutical Approaches. Biomedicines 2021;9:1168. [PMID: 34572354 DOI: 10.3390/biomedicines9091168] [Reference Citation Analysis]
5 Aarts P, Dudink K, Vossen ARJV, van Straalen KR, Ardon CB, Prens EP, van der Zee HH. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs 2021;81:1397-410. [PMID: 34283386 DOI: 10.1007/s40265-021-01566-2] [Reference Citation Analysis]
6 Narla S, Price KN, Sachdeva M, Shah M, Shi V, Hamzavi I, Alavi A, Lowes MA. Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019. J Am Acad Dermatol 2021;84:120-9. [PMID: 32497690 DOI: 10.1016/j.jaad.2020.05.114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Frew JW, Marzano AV, Wolk K, Join-lambert O, Alavi A, Lowes MA, Piguet V. A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. Journal of Investigative Dermatology 2021;141:316-324.e2. [DOI: 10.1016/j.jid.2020.06.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
8 Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐bourboulis EJ, Fabbrocini G, Frew JW, Fujita H, González‐lópez MA, Guillem P, Gulliver WPF, Hamzavi I, Hayran Y, Hórvath B, Hüe S, Hunger RE, Ingram JR, Jemec GB, Ju Q, Kimball AB, Kirby JS, Konstantinou MP, Lowes MA, Macleod AS, Martorell A, Marzano AV, Matusiak Ł, Nassif A, Nikiphorou E, Nikolakis G, Nogueira da Costa A, Okun MM, Orenstein LA, Pascual JC, Paus R, Perin B, Prens EP, Röhn TA, Szegedi A, Szepietowski JC, Tzellos T, Wang B, van der Zee HH. What causes hidradenitis suppurativa ?—15 years after. Exp Dermatol 2020;29:1154-70. [DOI: 10.1111/exd.14214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
9 Lu JD, Milakovic M, Ortega-Loayza AG, Marzano AV, Alavi A. Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. Expert Opin Investig Drugs 2020;29:1179-85. [PMID: 32880206 DOI: 10.1080/13543784.2020.1819981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Frew JW, Piguet V. Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa. J Invest Dermatol 2020;140:1323-6. [PMID: 32571498 DOI: 10.1016/j.jid.2020.02.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Johnston DGW, Kirby B, Tobin DJ. Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction? Exp Dermatol 2021;30:1554-68. [PMID: 34418166 DOI: 10.1111/exd.14451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano AV, Nikolakis G, Sayed CJ, Tzellos T, Wolk K, Prens EP. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 2021;30 Suppl 1:8-17. [PMID: 34085329 DOI: 10.1111/exd.14338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
13 Dajnoki Z, Somogyi O, Medgyesi B, Jenei A, Szabó L, Gáspár K, Hendrik Z, Gergely P, Imre D, Póliska S, Törőcsik D, Zouboulis CC, Prens EP, Kapitány A, Szegedi A. Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2021. [PMID: 34724272 DOI: 10.1111/jdv.17779] [Reference Citation Analysis]
14 Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. JAAD Int 2020;1:62-72. [PMID: 34409324 DOI: 10.1016/j.jdin.2020.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Scurtu LG, Simionescu O. Soluble Factors and Receptors Involved in Skin Innate Immunity-What Do We Know So Far? Biomedicines 2021;9:1795. [PMID: 34944611 DOI: 10.3390/biomedicines9121795] [Reference Citation Analysis]
16 Hembram P. An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. Bull Natl Res Cent 2021;45:123. [PMID: 34257504 DOI: 10.1186/s42269-021-00582-2] [Reference Citation Analysis]